Clinical Trial on S-PRG- Versus Nano-Hybrid Filled Resin-Composites

Objectives: This clinical study evaluated the clinical performance of resin composites based on S-PRG filler versus nano-hybrid filler technologies in Class I and Class II cavities.
Methods: Between February-2016 and November-2016, a total of 36 patients (17 male, 19 female, mean age: 29±9 years old), received randomly 36 pairs of restorations restored using either S-PRG filler (SI-R21204, SHOFU Inc., Japan) or nano-hybrid resin composite (Clearfil Majesty Posterior, Kuraray, Japan) in Class I and Class II cavities. Two operators performed all restorations using FL-Bond II (SHOFU Inc., Japan) and Clearfil SE Bond (Kuraray, Japan) adhesives respectively according to each manufacturer’s instructions. Two independent calibrated operators evaluated the restorations 2 weeks after placement (baseline), at 6 months using FDI criteria (Scores 1-5) for surface properties, post-operative sensitivity. The changes in the FDI parameters were analyzed using McNemar test (alpha= 0.05) and Kaplan-Meier.
Results: Thirty-six (50%) restorations completed their 1 year follow up. No tooth fractures, cases of occlusal wear or loss of contact points requiring repair, incidence of secondary caries, endodontic complications or post-operative sensitivity was noted with both materials. Patients rated the fillings themselves as highly satisfactory, with 18 patients giving the highest score of 1. All the characteristics were rated predominantly with high (1 or 2) scores for 1 year follow-up. Less distribution of scores was seen regarding color match with the tooth and surface staining. In total 36 restorations received score 1 or 2 for color match. As regards to surface staining, 34 restorations (94%) received score 1 or 2, 2 restorations (6%) received score 3. All restorations presented score 1 or 2 (excellent or good) for surface luster.
Conclusions: Over the one-year follow-up period, both resin composite fillings based on either S-PRG filler and nano-hybrid fillers are clinically acceptable.